Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...

The liability, safety, and accuracy questions underlying one creative proposal, in this week's AI Prognosis newsletter.

Novo Nordisk is set to soon unveil pivotal Phase 3 data on whether semaglutide — the blockbuster GLP-1 drug behind Ozempic ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

In a first-of-its-kind randomized trial, people who smoked weed consumed less alcohol in the two hours afterward than those ...

Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help ...

A unique Harvard program trains future physicians to recognize structural failures embedded within our health care system.

A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...

A federal bankruptcy court judge on Tuesday formally approved OxyContin maker Purdue Pharma’s plan to settle thousands of ...

Every physician needs to have a basic level of AI literacy now. That might require some sort of licensing exam.

Instead of hammering on the facts, these public health campaigners in North Dakota have fostered conversation over good food.

Also, we report on some dramatic new childhood vaccine policies that are under consideration, and see how few lower- and ...